← Leaderboards
Robert Richard Flavell
University Of California, San Francisco
$4,877,416
Attributed
$11,257,626
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,257,626 · 7
By mechanism
R01$10,092,936 · 5
R37$661,882 · 1
R21$502,808 · 1
Top collaborators
- Arun P. Wiita5 shared
- Rahul Aggarwal4 shared
- Henry F. Vanbrocklin4 shared
- Tejal A. Desai3 shared
- Sanjay Jain3 shared
- Youngho Seo3 shared
- Renuka Sriram3 shared
- David M Wilson3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Rahul Aggarwal$5,953,056
- Thomas Hope$3,566,163
- Felix Yi-Chung Feng$6,764,664
- Michael John Evans$10,372,266
- Lawrence Fong$19,816,074
Others in their field
Other Emerging Leaders on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Lynn Briscoe · Leidos Biomedical Research, Inc.$119,691,178
- Terry Drinkwine · Carahsoft Technology Corporation$93,011,563
Research focus
ImageMalignant NeoplasmsPositron-Emission TomographyBiodistributionTumorPhysiciansPre-ClinicalPre-Clinical ModelToxic EffectFutureRadiolabeledRadiopharmaceuticalsDetectionPhase I Clinical TrialsClinical TranslationMalignant Neoplasm Of ProstateAnimal ModelCohortProstate Cancer ModelClinical TrialsPatient CareImaging AgentPatient Derived Xenograft ModelSignal Transduction
Grant awards (19)
Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2$678,101
R01 · FY2025 · CA
Development of CD46 theranostics for imaging and treatment of multiple myeloma$670,219
R01 · FY2025 · CA · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,448
R01 · FY2025 · CA · contact PI
Molecular imaging of novel PARP inhibitor nanomedicine delivery$621,383
R01 · FY2025 · CA
Development of CD46 theranostics for imaging and treatment of multiple myeloma$636,706
R01 · FY2024 · CA · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$631,129
R01 · FY2024 · CA · contact PI
Molecular imaging of novel PARP inhibitor nanomedicine delivery$590,313
R01 · FY2024 · CA
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$805,361
R01 · FY2023 · AI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,250
R01 · FY2023 · CA · contact PI
Development of CD46 theranostics for imaging and treatment of multiple myeloma$656,800
R01 · FY2023 · CA · contact PI
Molecular imaging of novel PARP inhibitor nanomedicine delivery$589,327
R01 · FY2023 · CA
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$809,270
R01 · FY2022 · AI
Development of CD46 theranostics for imaging and treatment of multiple myeloma$670,212
R01 · FY2022 · CA · contact PI
Molecular imaging of novel PARP inhibitor nanomedicine delivery$576,944
R01 · FY2022 · CA
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$828,473
R01 · FY2021 · AI
A novel immunoPET imaging agent to guide treatment planning in lethal prostate cancer$661,882
R37 · FY2021 · CA · contact PI
Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancer$157,091
R21 · FY2020 · EB · contact PI
Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancer$157,103
R21 · FY2019 · EB · contact PI
Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancer$188,614
R21 · FY2018 · EB · contact PI